ImmunityBio (IBRX) Stock Explodes 30% on Massive Anktiva Revenue Beat

TLDR

• ImmunityBio stock jumped over 30% on Thursday after reporting Anktiva sales grew roughly 700% year-over-year to $113 million in 2025
• Fourth quarter 2025 revenue hit $38.3 million, up 20% from the prior quarter and 431% from the same period in 2024
• Saudi FDA approved Anktiva for metastatic non-small cell lung cancer, marking the first global approval for this indication
• The company also secured Saudi approval for Anktiva plus BCG in BCG-unresponsive bladder cancer, adding to U.S., U.K., and conditional EU approvals
• Wall Street analysts rate IBRX stock a Strong Buy with an average price target of $7.33, implying 85.57% upside potential

ImmunityBio stock closed Thursday at $3.95, marking a 30.79% gain for the session. The biotechnology company released preliminary 2025 results showing Anktiva revenue jumped from $15 million in 2024 to approximately $113 million.

ImmunityBio, Inc., IBRX

The therapy drove net product revenue growth that caught Wall Street’s attention. Fourth quarter 2025 revenue alone reached $38.3 million, up 20% from the previous quarter and 431% higher than the same period in 2024.

Trading volume spiked to 70.4 million shares, about 442% above the three-month average of 13 million shares. The stock has climbed steadily this week following multiple positive catalysts.

New Market Approvals Expand Geographic Reach

Saudi FDA granted approval for Anktiva in combination with checkpoint inhibitors for metastatic non-small cell lung cancer. This marks the first global approval for this indication.

The company also received Saudi approval for Anktiva plus BCG in BCG-unresponsive bladder cancer. ImmunityBio now holds approvals in the U.S., U.K., and conditional approval in the EU for this indication.

Earlier this week, the company released positive lung cancer data. The results point to potential new revenue streams as the therapy’s market expands.

Unit sales of Anktiva increased 750% in 2025 compared to 2024. The IL-15-based therapy activates T cells and natural killer cells to fight cancer.

Anktiva has shown strong results in bladder cancer patients. The treatment delivers high response rates and long-lasting benefits for those with BCG-unresponsive disease.

Clinical Trial Progress Continues

ImmunityBio is moving ahead of schedule in its Phase 2b trial for first-line, BCG-naïve bladder cancer. The company expects full enrollment in the first half of 2026.

The therapy’s rapid adoption reflects growing physician confidence. Demand has accelerated throughout 2025 as more treatment centers gain experience with Anktiva.

The S&P 500 added 0.27% Thursday while the Nasdaq Composite gained 0.25%. Biotech peers Incyte closed down 0.67% at $105.24, and Vertex Pharmaceuticals fell 2.36% to $438.92.

Wall Street analysts have assigned a Strong Buy consensus rating on IBRX stock based on three Buy ratings in the past three months. The average price target of $7.33 per share suggests 85.57% upside potential.

ImmunityBio went public in 2015 and has fallen 89% since its IPO. The stock’s market cap now stands at $3.9 billion.

The company’s 52-week range sits between $1.83 and $4.27. Gross margin reached 80.41% as product sales ramped up through 2025.

The post ImmunityBio (IBRX) Stock Explodes 30% on Massive Anktiva Revenue Beat appeared first on CoinCentral.